parkinson's disease triple agonist glp-1 gip glucagon clinical trial Full article: Therapeutic application of and receptor agonists in New strategies for the treatment

Saaoud F, Liu L, Xu K, et al

& Kim, M.-S

If regulatory submissions proceed as expected, the earliest plausible timeline for a market authorisation decision in the UK or Europe would be 2026 or 2027 though this is subject to the pace of regulatory review, the completeness of the submission package, and any additional data requests from the MHRA or EMA

plasma neurofilament light chain and glial fibrillary acidic protein, the fluid markers that track neuroaxonal injury and astrocytic activation, did not improve and in some analyses drifted slightly upward [1]

Fluorescent-Nitrogen-Doped Carbon Quantum Dots Derived from Citrus Lemon Juice: Green Synthesis, Mercury(II) Ion Sensing, and Live Cell Imaging

Riggs, B